CancerNetwork Members: Login | Register
 
CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
PATIENTS
NURSES
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » Thyroid Cancer

Oncology NEWS International. Vol. 18 No. 9
International News 

Canada sees mixed trends in thyroid cancer

By Fran Lowry | September 21, 2009

TORONTO—Two large, population-based studies with over 35 years of data revealed some of the factors that have influenced the incidence of thyroid cancer. Two key findings: Canadian men and people living in rural areas generally present with more advanced disease and the incidence of anaplastic thyroid cancer is waning. The studies were presented at the 2009 World Congress on Thyroid Cancer.

In the province of Ontario, men and patients who live in rural areas tend to present with larger thyroid tumors, according to a study led by Stephen Hall, MD, an otolaryngologist at Queen’s University in Kingston, Ontario. The study described the patients, the tumors, the surgical procedures, and the surgeons who treated differentiated thyroid cancer in the province from 1990 to 2002.

The study population consisted of 3,500 differentiated thyroid cancer patients from urban, suburban, and rural regions. Data sources included records from the Ontario Cancer Registry and the Cancer Research Institute at Queen’s University (oral session 3).

Dr. Hall reported that the number of differentiated thyroid cancers increased in the 12-year period. Most patients had tumors that were smaller than 1 cm or tumors that were between 2 and 4 cm; few patients had tumors larger than 4 cm. Patients who lived outside of Toronto, which is the most densely populated area of the province, tended to present with tumors larger than 2 cm. If they lived in a rural area—four of the seven regions in Ontario are designated as rural—they presented with still larger tumors. “This comes as no great surprise. This has to do with access to imaging and patient demand,” Dr. Hall said.

In most cases, initial treatment consisted of total thyroidectomy. The extent of surgery was influenced by gender, with total thyroidectomy performed more often in males than in females. However, age did not make a difference: the percentages of total thyroidectomies and partial thyroidectomies were the same for younger and older patients.

Tumor size was also a factor in the extent of surgery, although not to the degree that the investigators were expecting. Although most patients had a total thyroidectomy regardless of their tumor size, almost 60% of patients with tumors smaller than 1 cm had a total thyroidectomy. This percentage was roughly the same in patients who had tumors that were larger than 4 cm.

Meanwhile, in Manitoba, Ontario’s neighbor to the west, the incidence of anaplastic thyroid cancer has dropped, possibly as a result of iodine(Drug information on iodine) supplementation in the diet and less multinodular goiter. However, Hürthle thyroid cancer incidence has gone up.

Data from the Canadian Cancer Statistics showed a 100% nationwide increase in the incidence of thyroid cancer in males and a 90% increase in females in recent years, while mortality rates increased in males by 0.7% but were reduced by 1.5% in females, reported K. Alok Pathak, MS, DNB, an associate professor in the department of surgery at the University of Manitoba Faculty of Medicine in Winnipeg.

Dr. Pathak’s study looked at 1,702 consecutive thyroid cancer patients seen in Manitoba from 1970 to 2005. The median follow up was 152 months. The majority of patients (75%) were female, with a mean age at diagnosis of 48 years. Most patients had stage T1 or T2 disease, and 74% were node-negative at the time they presented. Only 4% presented with distant metastases. During the later part of the study period (2000-2005), 366 thyroid cancers were seen vs 160 earlier in the study (1970-1975). However, the five-year disease-specific survival steadily improved between 1970 and 2005, from 75.7% to 95%.

Also, the proportion of undifferentiated cancers fell from 19.4% (1970-1975) to 5.5% (2000-2005). Differentiated thyroid cancer accounted for almost 90% of all thyroid cancer cases in Manitoba. There was an increase in incidence of Hürthle cell cancer and a decrease in anaplastic thyroid cancers. Multivariate analysis showed that disease-specific survival was independently influenced by tumor histology and grade (hazard ratio [HR] = 26.1; P = .005), completeness of resection (HR = 82.9; P = .020), and age at diagnosis (HR = 1.1; P < .001). “In thyroid cancer, pathology is the determinant of successful outcome,” Dr. Pathak said. “In low-risk thyroid cancer, which represents 90% of our thyroid cancers, adequate surgery is more than enough; you don’t need to give adjuvant treatment for that. I think that is the important message.”

 

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
RELATED CONTENT

Medullary Thyroid Cancer in a 28-Year-Old Male
September 15, 2011
Cabozantinib Shows Promising Activity in Prostate Cancer Bone Metastases
August 24, 2011
Photosensitive Facial Rash Depicted Along with Polyarticular Arthralgias
April 29, 2011
Vandetanib Now Available to U.S. Patients with Advanced Medullary Thyroid Cancer
April 25, 2011
First Medullary Thyroid Cancer Drug is Approved
April 11, 2011
 
TOPIC INDEX

  • Bladder Cancer
  • Bone Metastases
  • Breast Cancer
  • CML
  • Colorectal Cancer
  • End-of-Life
  • GIST
  • Genetics Genomics
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Integrative Oncology
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Nausea & Vomiting
  • Palliative Care
  • Pancreatic Cancer
  • Practice Management
  • Practice & Policy
  • Prostate Cancer
  • RCC
  • Skin Cancer
  • Triple-Negative Breast
  • Testicular Cancer


More Topics 


 
FROM PHYSICIANS PRACTICE
'What They Should Really Teach in Medical School'
Julie Schopps, MD , February 6, 2012
The North Carolina-based pediatrician weighs in on why she thinks the real learning doesn't take place until students are out of the classroom.
Improve EHR Systems by Rethinking Medical Billing
Daniel Essin, MA, MD, February 6, 2012
Separating billing-related data from other clinical documentation and transmitting it to a billing system is not difficult …no matter how the charting is done.
Keeping Your Medical Practice’s Accounts Receivable on Track
P.J. Cloud-Moulds, February 4, 2012
Here are the minimum reports you should be running to keep an eye on your practices A/R.
Healthcare Providers Play Crucial Role in Helping Victims of Abuse
Stephen Hanson, PA-C , February 3, 2012
I would urge each and every one of you to be familiar with the warning signs of abuse, and the resources available to you all as healthcare providers.
Protecting Your Medical Practice's Data
Marisa Torrieri, February 3, 2012
Here's the scoop on how to implement a good data-backup plan at your office.
 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Management of Brain Metastases: Neurosurgical Considerations
  • Optimizing Outcomes of Advanced Prostate Cancer: Drug Sequencing and Novel Therapeutic Approaches
  • Head and Neck Tumors
  • A 28-Year-Old Woman Presents With a Long-Standing History of Intermittently Painful “Bumps” on Both Her Shoulders and Upper Back
  • Controversies in Oncologist-Patient Communication: A Nuanced Approach to Autonomy, Culture, and Paternalism
  • Ending the Shortage of Generic Oncology Drugs
  • Processed and Red Meat Consumption Linked to Slight Increase in Risk of Pancreatic Cancer
  • Controversies in Oncologist-Patient Communication: A Nuanced Approach to Autonomy, Culture, and Paternalism
  • Younger Breast Cancer Patients Have More Adverse Quality of Life Issues
  • New Way to Predict Prostate Cancer Severity—Size of Prostate
  • AL Amyloidosis: Who, What, When, Why, and Where
  • The Maze of PARP Inhibitors in Ovarian Cancer
  • The Circuitous Path of PARP Inhibitor Development in Epithelial Ovarian Cancer
  • Podcast: Dr. David Ahlquist on Advances in Colorectal Cancer Screening
  • Lung Cancer Screening: A New Era
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • When to Treat Myelodysplastic Syndromes
  • ASCO 2011: A Paradigm Shift in the Treatment of Endometrial Cancer
  • PSA Screening for Prostate Cancer Put Into Question By the U.S. Preventive Services Task Force
  • PSA Screening for Prostate Cancer Put Into Question By the U.S. Preventive Services Task Force
  • When to Treat Myelodysplastic Syndromes
  • ASCO 2011: A Paradigm Shift in the Treatment of Endometrial Cancer
  • Are We Ready for Neoadjuvant Therapy in Potentially Resectable Pancreatic Cancer?
  • Evolving Therapeutic Paradigms for Advanced Prostate Cancer
Click here to subscribe to our newsletter
 
JOB LISTINGS

Post a job

Powered by SearchMedica Jobs


CancerNetwork on Facebook

 

 
SearchMedica Search Result

Find peer-reviewed literature and websites for practicing medical professionals

CME on Thyroid Cancer
Evidence on Thyroid Cancer
Guidelines on Thyroid Cancer
Patient Education on Thyroid Cancer
Clinical Trials on Thyroid Cancer
Practical Articles on Thyroid Cancer
Research and Reviews on Thyroid Cancer
All "Thyroid Cancer" results


CancerNetwork | CME LLC | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2012 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy